# **Impact of Provider Selected Indication Requirement on Urine Test Utilization and Positivity**

Jessica A. Penney MD1, Angie Mae Rodday PhD2, Paola Sebastiani PhD2, David R. Snydman MD1, Shira Doron MD1

1 Division of Geographic Medicine and Infectious Disease, Tufts Medical Center, Boston, Massachusetts, United States

2 Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, United States

**Supplemental Material**

Urine tests

N = 17,220

3,707 tests excluded (repeat testing during admission)

Urine tests, first test from admission

N = 13,513

697 tests excluded for patients <18 years

Adult urine tests

N = 12,816

11,322 tests excluded for tests ordered as urinalysis with reflex culture

Adult urine isolated culture tests

N = 1494

**Figure 1 Data Selection for Isolated Urine Culture Study Inclusion**: Figure demonstrates the selection process to determine testing eligible for study inclusion and analysis.

**Table 1 Interrupted Time Series (ITS) Analysis Pre- and Post-Intervention Results with Difference between Periods**

|  |  |  |  |
| --- | --- | --- | --- |
|  | Pre-Intervention | Post-Intervention | Difference1 |
|  | Beta | Exp(beta) | p | Beta | Exp(beta) | p | Beta | p |
| Isolated UC Rate (per 1000 patient days) |
| *Intercept2* | 2.41 | 11.2 | <0.001 | 2.045 | 7.75 | <0.001 | -0.37 | 0.17 |
| *Slope3* | -0.017 | 0.98 | 0.23 | 0.029 | 1.03 | 0.73 | 0.012 | 0.54 |
| Proportion of all Urine Testing (%)4 |
| *Intercept* | -2.04 | 0.13 | <0.001 | -1.88 | 0.15 | <0.001 | 0.15 | 0.59 |
| *Slope* | 0.01 | 1.01 | 0.63 | -0.027 | 0.97 | 0.075 | -0.034 | 0.11 |
| CuLture Positivity (%)5 |
| *Intercept* | -1.31 | 0.27 | <0.001 | -1.32 | 0.27 | <0.001 | -0.0069 | 0.99 |
| *Slope* | -0.02 | 0.98 | 0.36 | -0.0003 | 0.99 | 0.99 | 0.019 | 0.52 |
| 1 Difference calculated as post-intervention minus pre-intervention beta2 Intercept represents rate at start of pre- and post-intervention period, respectively3 Slope represents pre-and post-intervention trend, respectively4 Proportion of all urine testing measured as isolated urine culture/all urine testing (isolated urine culture + UARC)5 Culture positivity measured as culture positive for organisms/isolated culture performed |

**Table 2 Sensitivity Interrupted Time Series (ITS) Analysis Removing COVID-19 Impacted Months**

|  |  |  |  |
| --- | --- | --- | --- |
|  | Pre-Intervention | Post-Intervention | Difference1 |
|  | Beta | Exp(beta) | p | Beta | Exp(beta) | p | Beta | p |
| Isolated UC Rate (per 1000 patient days) |
| *IntercepT2* | 2.41 | 11.2 | <0.001 | 2.13 | 8.41 | <0.001 | -0.28 | 0.26 |
| *Slope3* | -0.017 | 0.98 | 0.23 | 0.008 | 0.99 | 0.55 | 0.025 | 0.63 |
| Proportion of all Urine Testing (%)4 |
| *Intercept* | -2.04 | 0.13 | <0.001 | -1.79 | 0.17 | <0.001 | 0.25 | 0.38 |
| *Slope* | 0.01 | 1.01 | 0.62 | -0.029 | 0.97 | 0.05 | -0.019 | 0.08 |
| CuLture Positivity (%)5 |
| *Intercept* | -1.31 | 0.27 | <0.001 | -1.4 | 0.24 | <0.001 | -0.09 | 0.83 |
| *Slope* | -0.02 | 0.98 | 0.36 | -0.0008 | 1.00 | 0.97 | 0.019 | 0.51 |
| Sensitivity analysis performed by removing March-May 2020 1 Difference calculated as post-intervention minus pre-intervention beta2 Intercept represents rate at start of pre- and post-intervention period, respectively3 Slope represents pre-and post-intervention trend, respectively4 Proportion of all urine testing measured as isolated urine culture/all urine testing (isolated urine culture + UARC)5 Culture positivity measured as culture positive for organisms/isolated culture performed |